The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies
Open accessAbstract
BACKGROUND: Caspofungin (CAS) as salvage therapy for refractory invasive aspergillosis (IA) had a response rate of 45% among a heterogeneous group of patients. The use of CAS with other agents is appealing given its unique mechanism of action. Therefore, the authors retrospectively evaluated the efficacy and toxicity of CAS plus liposomal amphotericin B (LipoAMB) in patients with documented (definite or probable) or possible IA. METHODS: Patients were evaluable for outcome if they received CAS/LipoAMB for at least 7 days. Patients who received CAS and LipoAMB sequentially were excluded. All patients were evaluable for toxicity. Outcome was assessed weekly and at the end of therapy. Stable disease and progression were considered treatment failures. RESULTS: Forty‐eight patients with documented (n = 23) or possible (n = 25) IA were identified between March 2001 and December 2001. The majority of the patients (65%) received CAS/LipoAMB as salvage therapy for progressive IA despite 7 or more days of previous LipoAMB monotherapy. The overall response rate was 42%. No significant toxic effects were seen. Factors associated with failure at the end of therapy were documented IA (P = 0.03), significant steroid use before the study (P = 0.02), and duration of combination therapy for less than14 days (P =0.01). The response rate in patients with progressive documented IA was low (18%). CONCLUSIONS: The CAS/LipoAMB combination is a promising preemptive therapy for IA and was generally well tolerated. This combination might have limited benefit as salvage therapy for documented IA. Cancer 2003;98:292–9. © 2003 American Cancer Society. DOI 10.1002/cncr.11479
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
Denning, D. W., & Stevens, D. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.6.1147 · Cited by 899
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 15×
“Another comparison would be the efficacy of the CAS/LipoAMB combination versus the analogous experience with the use of CAS in combination with AMB in other tertiary-care oncology centers that care for a large number of patients at high risk for death due to IA.”
BackgroundInfluentialInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791 · cited 2×
“Invasive aspergillosis (IA) is a leading cause of infectious death in patients with hematologic malignancies.(1,2) Pneumonia is the most frequent clinical manifestation of this opportunistic mycosis.”
BackgroundPractice Guidelines for Diseases Caused by Aspergillus
Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W., Bennett, J. E., Walsh, T. J., Patterson, T. F., & Pankey, G. A. (2000) · Clinical Infectious Diseases · doi:10.1086/313756 · Cited by 789
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Minari, A., Husni, R., Avery, R. K., Longworth, D. L., DeCamp, M., Bertin, M., Schilz, R., Smedira, N., Haug, M. T., Mehta, A., et al. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.t01-2-02002.x · Cited by 351
Invasive Aspergillosis in 2002: An Update
Kontoyiannis, D., & Bodey, G. (2002) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-002-0699-z · Cited by 326
Self-citation
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationPulmonary aspergillosis: a clinical review
Kousha, M., Tadi, R., & Soubani, A. O. (2011) · European Respiratory Review · doi:10.1183/09059180.00001011 · Cited by 752
Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Self-citationLimper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Combination Antifungal Therapy for Invasive Aspergillosis
Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W., & Corey, L. (2004) · Clinical Infectious Diseases · doi:10.1086/423380 · Cited by 596
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Invasive fungal infections: a review of epidemiology and management options
Enoch, D. A., Ludlam, H. A., & Brown, N. M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46548-0 · Cited by 501
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
Singh, N., Limaye, A. P., Forrest, G., Safdar, N., Mu??oz, P., Pursell, K., Houston, S., Rosso, F., Montoya, J. G., Patton, P., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000202421.94822.f7 · Cited by 336
Self-citationCurrent Approaches to Diagnosis and Treatment of Invasive Aspergillosis
Segal, B. H., & Walsh, T. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-727so · Cited by 334
Factors associated with mortality in transplant patients with invasive aspergillosis
Baddley, J. W., Andes, D. R., Marr, K. A., Kontoyiannis, D. P., Alexander, B. D., Kauffman, C. A., Oster, R. A., Anaissie, E. J., Walsh, T. J., Schuster, M. G., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/652768 · Cited by 303
Self-citationDenning, D. W., Marr, K. A., Lau, W. M., Facklam, D. P., Ratanatharathorn, V., Becker, C., Ullmann, A. J., Seibel, N. L., Flynn, P. M., van Burik, J.-A. H., et al. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.03.003 · Cited by 294
Posaconazole: a broad-spectrum triazole antifungal
Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P., & Raad, I. I. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70297-8 · Cited by 285
Self-citationPulmonary aspergillosis: a clinical update
Zmeili, O. S., & Soubani, A. O. (2007) · QJM · doi:10.1093/qjmed/hcm035 · Cited by 278
Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
Self-citation(2003) · PubMed · Cited by 240
Caillot, D., Thiébaut, A., Herbrecht, R., de Botton, S., Pigneux, A., Bernard, F., Larché, J., Monchecourt, F., Alfandari, S., & Mahi, L. (2007) · Cancer · doi:10.1002/cncr.23109 · Cited by 190
“3 Median [range] 14 [13–15] 14 [10–38] Survival at EOT 14 (93) 15 (100) Survival at Wk 12 12 (80)y 15 (100)”
BackgroundCurrent status of antifungal susceptibility testing methods
Arikan, S. (2007) · Medical Mycology · doi:10.1080/13693780701436794 · Cited by 152
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
van Rhijn, N., Storer, I. S. R., Birch, M., Oliver, J. D., Bottery, M. J., & Bromley, M. J. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01542-4 · Cited by 86
Candoni, A., Mestroni, R., Damiani, D., Tiribelli, M., Michelutti, A., Silvestri, F., Castelli, M., Viale, P., & Fanin, R. (2005) · European Journal of Haematology · doi:10.1111/j.1600-0609.2005.00500.x · Cited by 67
Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro
Natesan, S. K., Chandrasekar, P. H., Alangaden, G. J., & Manavathu, E. K. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.10.015 · Cited by 32
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
McCarthy, M. W. (2022) · Drugs in R&D · doi:10.1007/s40268-021-00376-x · Cited by 28
Invasive Aspergillosis in Hematological Patients
Kimura, S.-I. (2016) · Medical Mycology Journal · doi:10.3314/mmj.57.j77 · Cited by 14
Metadata
- Authors
- Kontoyiannis, D. P., Hachem, R., Lewis, R. E., Rivero, G. A., Torres, H. A., Thornby, J., Champlin, R., Kantarjian, H., Bodey, G. P., & Raad, I. I.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-07-02
- Volume
- 98
- Issue
- 2
- Pages
- 292-299
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2170381561
- Cited by
- 287
- References
- 20
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.